Kumamoto University · Research Division of Life Sciences

Research keywords肝細胞癌・非B非C肝癌・肝性脳症・リファキシミン・肝内胆管癌・HCVスクリーニング・HBV治療薬・MASLD認知機能・M2BPGi

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.2026 · Journal of gastroenterology
• Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.2026 · Hepatology research : the official journal of the Japan Society of Hepatology
• Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.2026 · Alimentary pharmacology & therapeutics
• Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion.2025 · Journal of gastroenterology

• 新規エピゲノム解析技術によるHBV遺伝子型間で異なるcccDNA制御機構の解明2024 · 科学研究費助成事業
• 空間的遺伝子発現解析が拓くCdh1介在性の炎症性発癌機構の解明と新規予防戦略2021 · 科学研究費助成事業 基盤研究(C)
• 新規エピゲノム解析技術による新しいHBV-cccDNA制御メカニズムの解明2021 · 科学研究費助成事業 基盤研究(C)
• 栄養環境がもたらすエピゲノム制御変化の解明に基づく肝発癌増殖進展の制御2021 · 科学研究費助成事業 基盤研究(C)

• Official profile